Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
Davis-Ewart L, Atkins L, Ghanooni D, Diaz JE, Chuku CC, Balise R, DeVries BA, Miller-Perusse M, Ackley Iii D, Moskowitz JT, McCollister K, Fardone E, Hirshfield S, Horvath KJ, Carrico AW. Supporting treatment adherence for resilience and thriving (START): protocol for a mHealth randomized controlled trial. BMC Public Health. 2024 Aug 29; 24(1):2350.
-
Qin J, Scarinci I, Lu E, Senkomago V, Ngoc Nguyen DT, Abonales L, Soin K, Edilyong J, Reichhardt M, Marfel M, Simms K, Canfell K, Maxwell K, Saraiya M, Palafox N. Building Capacity for Cervical Cancer Prevention in U.S.-Affiliated Pacific Islands: The Pacific Against Cervical Cancer Project. J Womens Health (Larchmt). 2024 Jul; 33(7):839-847.
-
Ali AA, Kulkarni A, Bhattacharjee S, Diaby V. Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework. Pharmacoeconomics. 2024 Jul; 42(Suppl 2):211-224.
-
Dawson LP, Nehme E, Nehme Z, Zomer E, Bloom J, Cox S, Anderson D, Stephenson M, Ball J, Zhou J, Lefkovits J, Taylor AJ, Horrigan M, Chew DP, Kaye D, Cullen L, Mihalopoulos C, Smith K, Stub D. Chest Pain Management Using Prehospital Point-of-Care Troponin and Paramedic Risk Assessment. JAMA Intern Med. 2023 03 01; 183(3):203-211.
-
Jiang X, Diaby V, Vouri SM, Lo-Ciganic W, Parker RL, Wang W, Chang SH, Wilson DL, Henry L, Park H. Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs. Am J Prev Med. 2023 01; 64(1):96-104.
-
Abegaz TM, Diaby V, Sherbeny F, Ali AA. Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA. Clin Drug Investig. 2022 Jun; 42(6):501-511.
-
Tran PT, Riaz M, Chen Z, Truong CB, Diaby V. An Umbrella Review of the Cost Effectiveness of Human Papillomavirus Vaccines. Clin Drug Investig. 2022 May; 42(5):377-390.
-
Moreau LA, Holloway I, Fylan B, Hartley S, Cundill B, Fergusson A, Alderson S, Alldred DP, Bojke C, Breen L, Ismail H, Gardner P, Mason E, Powell C, Silcock J, Taylor A, Farrin A, Gale C. Using routine healthcare data to evaluate the impact of the Medicines at Transitions Intervention (MaTI) on clinical outcomes of patients hospitalised with heart failure: protocol for the Improving the Safety and Continuity Of Medicines management at Transitions of care (ISCOMAT) cluster randomised controlled trial with embedded process evaluation, health economics evaluation and internal pilot. BMJ Open. 2022 04 29; 12(4):e054274.
-
Diaby V, Babcock A, Huang Y, Moussa RK, Espinal PS, Janvier M, Soler D, Gupta A, Jayakar P, Diaz-Barbosa M, Totapally B, Sasaki J, Jayakar A, Salyakina D. Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States. Pharmacogenomics J. 2022 07; 22(4):223-229.
-
Wu X, Rabei R, Keller EJ, King B, Kothary N, Kohi M, Taylor A, Heller M. Tunneled Peritoneal Catheter vs Repeated Paracenteses for Recurrent Ascites: A Cost-Effectiveness Analysis. Cardiovasc Intervent Radiol. 2022 Jul; 45(7):972-982.